Publications
147
Citations
1,401
Est. group size
~11
Recurring co-author estimate
Active years
16
Publishing since 2011
Shawn Dason's work focuses on urologic cancers, particularly kidney (renal cell carcinoma), bladder (urothelial), and prostate cancer, with an emphasis on surgical management including complex procedures like tumor thrombectomy and vena cava surgery. Additional work examines healthcare economics such as Medicare reimbursement trends for urologic procedures and the cost implications of cancer treatments. This research combines surgical technique reporting, case studies, and health policy/economics analysis relevant to urologic oncology.
Publication output has grown over the last decade, rising from single digits annually around 2017-2018 to a peak of over 20 publications in 2025, indicating an increasing rate of research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- IP60-05 MEDICARE REIMBURSEMENT TRENDS ACROSS BENIGN UROLOGY SUBSPECIALTIES FROM 2002 TO 2025
The Journal of Urology · 2026
- Editorial Commentary
Urology Practice · 2025
- Editorial Comment on "Paratesticular Tumors: A Systematic Review and Proposed Risk-based Management Algorithm”
Urology · 2025
- National and Location-Specific Medicare Physician Fee Reimbursement Trends in Urologic Oncology From 2002 to 2024
Urology Practice · 2025
- MEDICARE PHYSICIAN FEE REIMBURSEMENT TRENDS FOR UROLOGIC ONCOLOGY PROCEDURES FROM 2002-2024
Urologic Oncology Seminars and Original Investigations · 2025
- V04-06 ROBOTIC PATCH CAVOPLASTY FOLLOWING VENA CAVAL RESECTION
The Journal of Urology · 2025
- Reno-Gonadal Venous Anastomosis for Right Renal Venous Drainage Following Juxtarenal Cavectomy for Renal Cell Carcinoma
Journal of Kidney Cancer and VHL · 2025
- Reno-Gonadal Venous Anastomosis for Right Renal Venous Drainage Following Juxtarenal Cavectomy for Renal Cell Carcinoma.
PubMed · 2025
- Editorial Comment on “Development and External Validation of a Local Pelvic Recurrence Risk Score After Radical Cystectomy: Identifying the Ideal Candidate for Adjuvant Radiation Clinical Trials”
Urology · 2025
- Beyond Efficacy: Cost and Resource Implications of First-Line Systemic Therapies for Metastatic Renal Cell Carcinoma
JCO Oncology Practice · 2025
- Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer
JCO Precision Oncology · 2024
- V09-09 ROBOTIC FEMORAL HERNIA REPAIR FOLLOWING RAIL (ROBOT-ASSISTED INGUINAL LYMPHADENECTOMY)
The Journal of Urology · 2024
- Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
Urologic Clinics of North America · 2023
- Genomic heterogeneity as a barrier to precision oncology in urothelial cancer
Cell Reports · 2022
- V13-07 INFERIOR VENA CAVA MANAGEMENT DURING LEFT-SIDED LEVEL III TUMOR THROMBECTOMY
The Journal of Urology · 2022
- The Journal of Urology×30
- Journal of Clinical Oncology×12
- Urology Practice×5
- Urology×5
- Canadian Urological Association Journal×4
- Debra L. Zynger
Medicine · The Ohio State University
- Michael Gong
Medicine · The Ohio State University
- Courtney Yong
Medicine · Indiana University
- Daniel Sidhom
Medicine · Indiana University
- Michael O. Koch
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile